Key Market Indicators
Poland's pharmaceutical research and development (R&D) expenditure is projected to hit approximately $481 million in purchasing power parity (PPP) by 2028, up from around $349 million in 2023. This marks an average annual growth rate of 5.1%. Since 2010, Poland has seen a consistent year-on-year increase in its pharmaceutical supply, averaging a growth rate of 2.9%. In the global rankings for 2023, Poland secured the 9th position, having been overtaken by Taiwan, which also recorded an expenditure of roughly $349 million PPP. Leading the global rankings, China, Germany, and South Korea occupied the second, third, and fourth positions, respectively.
